Grethe Nørskov Rasmussen
Corporate Officer/Principal at FLUOGUIDE A/S
Net worth: 2 M $ as of 2024-04-29
Profile
Grethe Nørskov Rasmussen is currently the Chief Development Officer at FluoGuide A since 2019.
Prior to this, she was the Senior Vice President-Product Development at Ascendis Pharma A from 2008 to 2019.
Before that, she worked as the Vice President-Protein Science at Maxygen, Inc. from 2000 to 2007 and as a Principal at Novo Nordisk A from 1989 to 2000.
Dr. Rasmussen earned her doctorate degree from the Technical University of Denmark in 1989.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
FLUOGUIDE A/S
3.06% | 2023-09-29 | 373,185 ( 3.06% ) | 2 M $ | 2024-04-29 |
Grethe Nørskov Rasmussen active positions
| Companies | Position | Start |
|---|---|---|
| FLUOGUIDE A/S | Corporate Officer/Principal | 2018-12-31 |
Former positions of Grethe Nørskov Rasmussen
| Companies | Position | End |
|---|---|---|
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 2018-12-31 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
| NOVO NORDISK A/S | Corporate Officer/Principal | - |
Training of Grethe Nørskov Rasmussen
| Technical University of Denmark | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| FLUOGUIDE A/S | Health Technology |
| Private companies | 1 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
- Stock Market
- Insiders
- Grethe Nørskov Rasmussen
